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call for NomiNaTioNs
ALUMNI AWARDS of MERIT
The Executive Board of the Veterinary Medical 
Alumni Society is seeking nominations for the 
2010 Alumni Award of Merit and other awards for 
distinguished Penn Vet Alumni. Alumni include 
matriculating graduates, as well as interns, residents 
and post-doctoral fellows.
To be presented at the Penn Annual Conference 
in March, 2011, these awards are given to alumni 
stars who have made outstanding contributions to 
their profession and to the School, through their 
contributions that advance knowledge in biomedicine, 
promote the welfare of animals through public 
education of animal owners and benefit society 
through civic activities that foster the advancement of 
the profession and the School’s good name. 
The Veterinary Medical Alumni Society Board is 
seeking any and all candidates, but specifically from 
2010 reunion classes – or classes ending in ’5 or ‘10. 
Please forward your anonymous or signed nominations 
to Coreen M. Haggerty, Director of Alumni Relations, 
at 215.898.1481 or haggertc@vet.upenn.edu.
www.vet.upenn.edu/bellwether 21
researchbr ie fs
Improving treatment options for  
feline squamous cell carcinoma 
Using polyamines and combination  
therapy to inhibit cell growth
Dr. John Lewis, assistant 
professor of Dentistry and 
Oral Surgery, Department 
of Clinical Studies in 
Philadelphia and associate 
director of Mari Lowe 
Center for Comparative 
Oncology, first felt the 
frustration of dealing with 
feline oral squamous cell carcinoma (SCC) while on staff 
at a small animal practice in North Carolina. Although 
surgery can be curative in some cases, cats rarely show 
symptoms until the cancer has advanced to an inoperable 
size. In addition, oral SCC has historically been minimally 
responsive to radiation therapy and current chemotherapy 
options. When the opportunity arose, Dr. Lewis jumped 
at the chance to join a residency program at Penn Vet 
to further explore surgical and non-surgical options for 
improving the outcome for SCC patients.
SCC is the most common feline oral tumor, representing 
70 percent of feline oral tumors. Since the median survival 
time from diagnosis to death or euthanasia is approximately 
60 days, there is much room for improvement in treatment 
modalities. Dr. Lewis saw an opportunity to improve 
treatment options for patients who were not surgical 
candidates. In conjunction with Dr. Tom O’Brien’s group 
at Lankenau Institute for Medical Research, Dr. Lewis and 
colleagues in Penn Vet’s Oncology Section and Dentistry 
and Oral Surgery Service embarked on a Phase I/II 
clinical trial of polyamine inhibitor therapy for cats with 
spontaneously occurring oral SCC. 
Polyamines are ubiquitous amino acid derived 
compounds that have been widely implicated in the 
growth and development of many mammalian tissues. 
When cellular polyamine synthesis is inhibited, cell growth 
is stopped or severely retarded. Providing exogenous 
polyamines restores the growth of cells. Polyamine 
synthesis is increased in many types of cancers and 
expression levels of the rate limiting synthetic enzyme, 
ornithine decarboxylase (ODC), are often increased as 
well. As Dr. O’Brien’s original studies indicated that the 
ODC inhibitor difluoromethylornithine (DFMO) was 
effective in treating experimentally induced SCC in mice, 
a Phase I/II study was carried out to determine whether 
cats tolerate DFMO. Results of this study will soon be 
submitted for publication, but the relatively minimal side 
effects seen with DFMO protocols suggest that further 
studies are justified for use in a clinical setting.
Although targeting polyamine synthesis with ODC 
inhibitors can be effective for cancer cell growth 
inhibition, most eukaryotic cells have a polyamine 
transport system in their cell membrane that facilitates 
internalization of extracellular polyamines. Thus, 
polyamine synthesis inhibitors will only fight half 
the battle in reducing intracellular polyamine levels. 
To overcome this limitation, Dr. Lewis’ latest study 
focuses on treating cats affected by oral SCC with a 
combination therapy utilizing DFMO and a polyamine 
transport inhibitor developed by MBF Therapeutics. 
The Veterinary Clinical Investigation Center (VCIC) has 
greatly facilitated all phases of this second study, and Dr. 
Lewis further credits the team effort put forth between 
Dr. Karin Sorenmo, Dr. Erika Krick, Dr. Nicola Mason, 
members of the Dentistry and Oral Surgery Service, 
Sections of Radiology and Pathology and practitioners 
who have shown interest in referring cases. While this 
study is still ongoing, it is the hope that such combined 
therapy will halt cancer growth but not significantly 
diminish other important quality of life aspects.
While increased research on feline oral SCC will 
undoubtedly benefit feline patients, it is Dr. Lewis’ hope 
that such research will also have important implications 
for human patients.
